Science in Dyslipidemia Disease
Get a 360º view and stay up-to-date on cardiovascular disease with content selected for you
ODYSSEY Outcomes
Odyssey Outcomes - Mortality
NEJM Odyssey Outcomes
PCSK9 inhibitors and ACS
Odyssey Outcomes - CABG Results
Odyssey Outcomes - PVD Results
%20from%20the%20SAFEHEART%20registry.jpeg)
Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry
PCSK9 Inhibitors in Cardiovascular Disease
Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
ESC/EAS 2019 International Guidelines
Odyssey Outcomes - Total Events Analysis
Odyssey Outcomes - PVD Sub-analysis
Inspiration and innovation
Get inspired and stay at the forefront of innovation with the following resources
Atherosclerosis: Identifying risks and improving outcomes
Improving Lipid Management for Patients Post-ACS
Lipid Management in Patients with ACS/ASCVD
Act Now for Your ACS Patients: Summary
Lp(a) as ASCVD Risk Factor
EAS guidance regarding combining lipid-modifying therapy
Act Now for Your ACS Patients: Patient Identification
Metabolic Risk Factors and Effect of Alirocumab on CV Events
Act Now for Your ACS Patients: Optimise Your ACS Pathway
Identifying and Treating Patients with High Lipidaemia Risk Post-ACS
Lp(a) and PCSK9 inhibition in nominally controlled LDL-C
The Role of the Patient in Achieving LDL-C Target
Events
Stay up to date and register for the latest events and view webinar recordings.
.png)
24:30
Dyslipidemia Webinar
Dyslipidemia Webisodes: Mortality data with Prof. Tunon
.png)